At a glance
A short-acting GHRH-related research record that requires precise naming.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Growth hormone signaling is the central research theme. Results for long-acting CJC-1295 cannot simply be assigned to a no-DAC formulation.[2][5][6]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of CJC-1295 NO DAC.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg | 6 units (0.06 mL) |
| Weeks 3–4 | 150 mcg | 9 units (0.09 mL) |
| Weeks 5–6 | 200 mcg | 12 units (0.12 mL) |
| Weeks 7–12 | 250–300 mcg | 15–18 units (0.15–0.18 mL) |
Frequency: Inject once daily subcutaneously, typically at bedtime to align with natural nocturnal GH pulsatility[2][3]. For ≤10‑unit (≤0.10 mL) administrations (Weeks 1–4), consider 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Stimulate pulsatile GH release and elevate IGF‑1 levels to support body composition, recovery, and overall metabolic health[2][5].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 100–300 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 100–150 mcg daily; increase by ~50 mcg every 1–2 weeks as tolerated.
- Target: 200–300 mcg daily by Weeks 5–12.
- Frequency: Once per day (subcutaneous), preferably at bedtime.
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Administer at bedtime to align with natural nocturnal GH pulses; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at 2–8 °C (35.6–46.4 °F); for extended storage, freeze at ≤−20 °C (≤−4 °F); minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 1–2 weeks; avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[12].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[12][13].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[12].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[14].
Materials & quantity planning
Source materials checklist · 5 mg
Plan based on an 8–12 week daily protocol with gradual titration.
-
Peptide Vials (CJC-1295 NO DAC, 5 mg each):
- 8 weeks ≈ 2 vials
- 12 weeks ≈ 3 vials
- 16 weeks ≈ 4 vials
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 12 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 16 weeks (4 vials): 12 mL → 2 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
- 02
- 03
Research publication
American Journal of Physiology (2006) — Alba et al.: Once‑daily CJC-1295 normalizes growth in GHRH knockout mice (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Public health resource
PMC — Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum IGF‑1 Levels (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Research publication
PMC — Effects of GHRH Analog (Tesamorelin) on Endogenous GH Pulsatility and Insulin Sensitivity (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 07
Research publication
PMC — Sermorelin: a better approach to management of adult‑onset growth hormone insufficiency (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 08
Research publication
PMC — Beyond the androgen receptor: role of GHS in body composition in hypogonadal males (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Research publication
PMC — The Safety and Efficacy of Growth Hormone Secretagogues (Review) (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Public health resource
PMC — GHRH Effects on Brain GABA Levels in Mild Cognitive Impairment and Healthy Aging (opens in a new tab)ncbi.nlm.nih.gov
Back to overview ↑ - 11
Research publication
PubMed — Sermorelin: review of its use in diagnosis and treatment of GH deficiency (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 12
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 13
Public health resource
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections (opens in a new tab)www.cdc.gov
Back to overview ↑ - 14
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 15
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.